• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of Anticoagulants and Dosing Appropriateness of Apixaban for New-Onset Atrial Fibrillation Among Hemodialysis Patients.

作者信息

Zhuo Min, Paik Julie M, Tsacogianis Theodore N, Desai Rishi J

机构信息

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Renal Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

出版信息

Am J Kidney Dis. 2022 Jun;79(6):909-912. doi: 10.1053/j.ajkd.2021.08.014. Epub 2021 Sep 25.

DOI:10.1053/j.ajkd.2021.08.014
PMID:34571068
Abstract
摘要

相似文献

1
Use of Anticoagulants and Dosing Appropriateness of Apixaban for New-Onset Atrial Fibrillation Among Hemodialysis Patients.血液透析患者中新发房颤患者抗凝剂的使用及阿哌沙班的剂量适宜性
Am J Kidney Dis. 2022 Jun;79(6):909-912. doi: 10.1053/j.ajkd.2021.08.014. Epub 2021 Sep 25.
2
Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.达比加群、利伐沙班和阿哌沙班与房颤中高 TTR 的华法林比较。
Thromb Res. 2018 Jul;167:113-118. doi: 10.1016/j.thromres.2018.05.022. Epub 2018 May 17.
3
Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation.影响非瓣膜性心房颤动患者卒中预防选用非维生素 K 拮抗剂口服抗凝剂的因素。
J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):656-664. doi: 10.1177/10742484211049919. Epub 2021 Sep 24.
4
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.英国背景下新型口服抗凝剂预防心房颤动患者中风和全身性栓塞的成本效益比较。
Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.
5
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.一项关于慢性肾脏病和透析合并心房颤动患者使用直接口服抗凝剂的系统评价。
Nephrol Dial Transplant. 2019 Feb 1;34(2):265-277. doi: 10.1093/ndt/gfy031.
6
Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.非瓣膜性心房颤动患者口服抗凝药的持续性：一项使用德国初级保健数据的队列研究。
PLoS One. 2017 Oct 10;12(10):e0185642. doi: 10.1371/journal.pone.0185642. eCollection 2017.
7
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.新型口服抗凝剂用于心房颤动患者的疗效及安全性比较
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.
8
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.阿哌沙班与其他新型口服抗凝药预防心房颤动卒中的成本效益比较。
Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.
9
Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis.利伐沙班或阿哌沙班在 4-5 期慢性肾脏病或透析患者中的房颤治疗效果。
Cardiovasc Drugs Ther. 2021 Apr;35(2):273-281. doi: 10.1007/s10557-021-07144-8. Epub 2021 Feb 4.
10
Comparative Effectiveness of Rivaroxaban, Apixaban, and Warfarin in Atrial Fibrillation Patients With Polypharmacy.利伐沙班、阿哌沙班和华法林在多药治疗的心房颤动患者中的疗效比较。
Stroke. 2020 Jul;51(7):2076-2086. doi: 10.1161/STROKEAHA.120.029541. Epub 2020 Jun 10.

引用本文的文献

1
Apixaban dosing in hemodialysis - can drug level monitoring mitigate controversies?阿哌沙班在血液透析中的剂量 - 药物水平监测能否缓解争议？
BMC Nephrol. 2024 Oct 9;25(1):338. doi: 10.1186/s12882-024-03782-w.
2
Factor Xa Inhibitors Versus Vitamin K Antagonists in Atrial Fibrillation Patients with End-Stage Kidney Disease on Dialysis: A Meta-Analysis.Xa 因子抑制剂与维生素 K 拮抗剂在透析终末期肾病伴心房颤动患者中的比较：一项荟萃分析。
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241271423. doi: 10.1177/10760296241271423.
3
Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study.
比较 ADVANCED CKD 合并心房颤动患者华法林、利伐沙班和阿哌沙班的安全性和有效性：美国全国队列研究。
Am J Kidney Dis. 2024 Mar;83(3):293-305.e1. doi: 10.1053/j.ajkd.2023.08.017. Epub 2023 Oct 13.